Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
Electromed, Inc. (NYSE American: ELMD) is a medical device company that develops, manufactures, and sells airway clearance therapy products, including the SmartVest® Airway Clearance System, for patients with compromised pulmonary function. Company news often highlights its role as a leader in airway clearance technologies and its focus on High Frequency Chest Wall Oscillation (HFCWO) therapy, particularly in the homecare setting.
Newsflow for Electromed frequently centers on financial results, such as quarterly and annual earnings releases that detail net revenues, operating income, net income, and segment performance in direct homecare and non-homecare markets. These announcements often discuss trends in referrals and approvals, sales force expansion, and gross margin dynamics, as well as commentary from management on operational execution and efficiency initiatives.
Investors can also expect corporate and capital markets updates, including announcements about share repurchase authorizations approved by the board of directors and index-related milestones, such as Electromed’s addition to the Russell 2000® and Russell 3000® indexes. The company issues press releases when it schedules earnings conference calls and webcasts, providing dial-in details and replay information.
Another recurring category of news involves investor conference participation. Electromed regularly announces its presence at events hosted by organizations such as Noble Capital Markets, LD Micro, Canaccord Genuity, and Investor Summit, where management presents the company’s airway clearance business and growth strategy to institutional and other investors.
For readers tracking ELMD, this news page provides a centralized view of Electromed’s earnings announcements, capital allocation decisions, index inclusions, and investor outreach activities, offering context on how the company is executing its strategy in the airway clearance therapy market.
Electromed (NYSE: ELMD) reported record Q2 FY2026 results for the three months ended December 31, 2025, with net revenues of $18.9M (+16.3% YoY), operating income $3.6M (+42.4% YoY), and net income $2.8M ($0.32 diluted EPS, +40.3% YoY). Homecare revenue led growth, rising 18.4% to $17.3M.
The company repurchased common stock ($2.8M in Q2; $3.8M six months), finished the quarter with $13.8M cash, no debt, and $45.4M equity.
Electromed (NYSE American: ELMD) will report fiscal 2026 second quarter results for the period ended December 31, 2025 on Tuesday, February 10, 2026 after market close. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors may join by phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or listen via the live webcast in the Investor Relations section of Electromed's website. Replays will be available by phone at (844) 512-2921 (Domestic) or (412) 317-6671 (International) using Access ID 10206198, and via the Investor Relations Events & Presentations page.
Electromed (NYSE American: ELMD) will present at NobleCon21, Noble Capital Markets' 21st Annual Emerging Growth Equity Conference, on Wednesday, December 3, 2025 at Florida Atlantic University in Boca Raton, Florida.
Jim Cunniff, Electromed's President and Chief Executive Officer, will present at 5:00 PM ET. A video webcast of the presentation will be available the following day on Electromed's Events & Presentations page and on the Noble Capital Markets conference catalog at www.nobleconference.com.
Electromed (NYSE American: ELMD) reported Q1 FY 2026 results for the three months ended September 30, 2025, with net revenues up 15.1% to $16.9M and net income up 44.9% to $2.1M ($0.25 diluted EPS). Operating income rose 37.8% to $2.7M. Homecare revenue was $14.9M; hospital revenue grew 51.7% to $1.047M and distributor revenue rose 41.2% to $829K. Gross profit was $13.2M (78.1% of sales). The board approved a $10M stock repurchase authorization. As of September 30, 2025, cash was $14.1M, accounts receivable $24.8M, no debt, working capital $35.8M, and shareholders’ equity $44.7M.
Management completed a manufacturing optimization plan and implemented a new CRM to boost sales productivity.
Electromed (NYSE: ELMD) will release its fiscal 2026 first quarter results for the period ended September 30, 2025 on Wednesday, November 12, 2025 after market close. Management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.
Investors can join by phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International), or listen via a live webcast in the company’s Investor Relations site. Replays will be available by phone at (844) 512-2921 (Domestic) or (412) 317-6671 (International) using Access ID 10203773, and online in the Events & Presentations section of the Investor Relations site.
Electromed (NYSE American: ELMD) will participate in the LD Micro Main Event XIX conference in San Diego, October 19-21, 2025. CEO Jim Cunniff will present on Monday, October 20, 2025 at 10:00 AM PT.
Investors can watch a live webcast via the Electromed Investor Relations site under Events & Presentations; institutional investors can register for the conference and request one-on-one meetings through LD Micro representatives.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has announced a new $10.0 million share repurchase authorization approved by its Board of Directors on September 9, 2025. This follows the completion of their previous buyback program in Q4 fiscal 2025.
The company will execute the repurchases through various means including open market transactions, private negotiations, and block trades, with timing and volume based on market conditions. CEO Jim Cunniff highlighted that the decision stems from strong operational performance and robust cash reserves, demonstrating the company's commitment to enhancing long-term shareholder value.
[ "New $10.0 million share repurchase program authorized", "Strong operational performance reported by management", "Robust cash reserves available for buyback execution", "Successfully completed previous share repurchase program in Q4 2025" ]Electromed (NYSE American: ELMD), a leader in airway clearance technologies, reported exceptional financial results for Q4 and FY 2025. The company achieved record quarterly revenue of $17.4 million (up 17.3%) and record annual revenue of $64.0 million (up 17.0%). Q4 net income reached $2.2 million ($0.25 per share), while FY 2025 net income was $7.5 million ($0.85 per share).
The company's direct homecare business grew 14.8% in Q4 and 15.7% annually, supported by 62 field sales employees. Operating income surged 46.8% for the full year to $9.7 million. Electromed maintained a strong financial position with $15.3 million in cash, no debt, and completed a $10.0 million share repurchase during FY 2025. The company was also added to the Russell 2000® and 3000® indexes in June 2025.
Electromed (NYSE American: ELMD), a leader in airway clearance technologies, has scheduled its fiscal 2025 fourth quarter financial results announcement for August 26, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day. Investors can join via phone at (844) 826-3033 (Domestic) or (412) 317-5185 (International). A webcast will be available through the company's Investor Relations website.
For those unable to attend live, a replay will be accessible by phone using Access ID 10201085, and through the company's website.
Electromed (NYSE American: ELMD), a leader in innovative airway clearance technologies, has announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. The conference will take place from August 12-14, 2025 in Boston, MA.
President and CEO Jim Cunniff, along with CFO Brad Nagel, will deliver a presentation on Tuesday, August 12 at 12:30 pm ET. Investors can access the live webcast through the company's Investor Relations website, and institutional investors have the opportunity to request one-on-one meetings through Canaccord Genuity.